drugbank-id,name,type,description,state,indication,mechanism-of-action,food-interactions,targets
"['DB00001', 'BTD00024', 'BIOD00024']",['Lepirudin'],biotech,"['Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches.[L41539] Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end).[A246609] \r\n\r\nLepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and platelet factor 4. This activates endothelial cells and platelets and enhances the formation of thrombi.[A246609] Bayer ceased the production of lepirudin (Refludan) effective May 31, 2012.[L41574]']",['solid'],"['Lepirudin is indicated for anticoagulation in adult patients with acute coronary syndromes (ACS) such as unstable angina and acute myocardial infarction without ST elevation. In patients with ACS, lepirudin is intended for use with [aspirin].[L41539] Lepirudin is also indicated for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and associated thromboembolic disease in order to prevent further thromboembolic complications.[L41539]']","['Lepirudin is a direct thrombin inhibitor used as an anticoagulant in patients for whom heparin is contraindicated.[L41539,A3] Thrombin is a serine protease that participates in the blood-clotting cascade, and it is formed by the cleavage of pro-thrombin. Active thrombin cleaves fibrinogen and generates fibrin monomers that polymerize to form fibrin clots.[A246624]\r\n\r\nLepirudin binds to the catalytic and substrate-binding sites of thrombin, forming a stable, irreversible and non-covalent complex.[A246609] This blocks the protease activity of thrombin and inhibits the coagulation process. Each molecule of lepirudin binds to a single molecule of thrombin,[L41539] and unlike [heparin], it is able to inhibit thrombin in both its clot-bound or free states.[A246609]']","[{'food-interaction': ['Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include chamomile, garlic, ginger, ginkgo and ginseng.']}]","[{'target': [{'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1703'], 'pubmed-id': ['10505536'], 'citation': ['Turpie AG: Anticoagulants in acute coronary syndromes. Am J Cardiol. 1999 Sep 2;84(5A):2M-6M.']}, {'ref-id': ['A1705'], 'pubmed-id': ['10912644'], 'citation': ['Warkentin TE: Venous thromboembolism in heparin-induced thrombocytopenia. Curr Opin Pulm Med. 2000 Jul;6(4):343-51.']}, {'ref-id': ['A1707'], 'pubmed-id': ['11055889'], 'citation': ['Eriksson BI: New therapeutic options in deep vein thrombosis prophylaxis. Semin Hematol. 2000 Jul;37(3 Suppl 5):7-9.']}, {'ref-id': ['A1709'], 'pubmed-id': ['11467439'], 'citation': ['Fabrizio MC: Use of ecarin clotting time (ECT) with lepirudin therapy in heparin-induced thrombocytopenia and cardiopulmonary bypass. J Extra Corpor Technol. 2001 May;33(2):117-25.']}, {'ref-id': ['A1711'], 'pubmed-id': ['11807012'], 'citation': ['Szaba FM, Smiley ST: Roles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo. Blood. 2002 Feb 1;99(3):1053-9.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L41539'], 'title': ['Health Canada Approved Drug Products: Refludan (lepirudin) lyophilized powder for intravenous injection'], 'url': ['https://pdf.hres.ca/dpd_pm/00004023.PDF']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}]}]"
"['DB00002', 'BTD00071', 'BIOD00071']",['Cetuximab'],biotech,"['Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF).[A227973] EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis.[A228083] EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells [A227973] and EGFR overexpression has been linked to more advanced disease and poor prognosis.[A227963] EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis.[A228083] _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts.[A227963]\r\n\r\nApproved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic colorectal cancer with a BRAF V600E mutation.[A227963,L39045] It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer.[L31418] Cetuximab is administered via intravenous infusion and is used as monotherapy or in combination with other chemotherapies, including platinum agents, radiation therapy, [leucovorin], [fluorouracil], and [irinotecan].[L30448]']",['liquid'],"['Cetuximab indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. It is indicated for treating a recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. It is indicated for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.[L30448]\r\n\r\nCetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination that includes [leucovorin], [fluorouracil], and [irinotecan]; in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy; or as monotherapy in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.[L30448]\r\n\r\nAdditionally, cetuximab is also indicated for metastatic colorectal cancer that is BRAF V600E mutation-positive (as determined by an FDA-approved test) in combination with [encorafenib] but only after prior therapy.[L39045]\r\n\r\nCetuximab is not indicated for the treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.[L30448]']","['The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein and a type I receptor tyrosine kinase expressed on both normal and malignant cells. It has been investigated as a therapeutic target for anticancer treatment, as it is often upregulated in cancer types, including head and neck, colon, and rectal cancers.[L30448] When activated by its ligand, EGFR undergoes a conformational change and dimerization to form homodimers or heterodimers with another member of the ErbB family of receptors. Dimerization of EGFR activates the intracellular tyrosine kinase region of EGFR and promotes autophosphorylation, initiating a series of downstream signalling cascades, including cell differentiation, proliferation, migration, angiogenesis, and apoptosis. This EGFR signalling pathway is often dysregulated in cancer cells, leading to aberrant cell growth and enhanced cell survival.[L31418]\r\n\r\nCetuximab is a monoclonal antibody that binds specifically to the EGFR on both normal and tumour cells to competitively inhibit the binding of epidermal growth factor (EGF) and other ligands that are produced by normal and tumour tissue epithelial cells.[A11, L30448] Upon binding to domain III of EGFR - which is the binding site for its growth factor ligands - cetuximab prevents the receptor from adopting an extended conformation and thereby inhibits EGFR activation, as well as phosphorylation and activation of receptor-associated kinases (MAPK, PI3K/Akt, Jak/Stat).[A11, A228078] Inhibition of the EGFR signalling pathway ultimately leads to inhibition of cell cycle progression, cell survival pathways, and tumour cell motility and invasion.[A227963] Cetuximab also induces cell apoptosis and decreases matrix metalloproteinase and vascular endothelial growth factor (VEGF) production.[A228078, L30448] _In vitro_, cetuximab was shown to inhibit tumour angiogenesis.[A227978] Binding of cetuximab to EGFR also results in internalization of the antibody-receptor complex, leading to an overall downregulation of EGFR expression.[A227973]\r\n\r\nK-ras is a small G-protein downstream of EGFR that plays an important role in promoting the EGFR signalling cascade: in some malignant cells, K-ras can acquire activating mutations in exon 2 [L31418] and thus be continuously active regardless of EGFR regulation.[L30448] Since mutant Ras proteins can isolate the pathway from the effect of EGFR, K-Ras mutations can render EGFR inhibitors like cetuximab ineffective in exerting anti-tumour effects.[L30448, L31418] Cetuximab is thus only limited in its use for K-Ras wild-type, EGFR-expressing cancers.[L30448]']",[None],"[{'target': [{'id': ['BE0000767'], 'name': ['Epidermal growth factor receptor'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A227973'], 'pubmed-id': ['15821783'], 'citation': ['Harding J, Burtness B: Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Epidermal growth factor receptor'], 'general-function': ['Ubiquitin protein ligase binding'], 'specific-function': ['Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.Isoform 2 may act as an antagonist of EGF action.'], 'gene-name': ['EGFR'], 'locus': ['7p12'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['646-668'], 'signal-regions': ['1-24'], 'theoretical-pi': ['6.67'], 'molecular-weight': ['134276.185'], 'chromosome-location': ['7'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3236']}, {'resource': ['GenAtlas'], 'identifier': ['EGFR']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X00588']}, {'resource': ['GenBank Protein Database'], 'identifier': ['757924']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1797']}, {'resource': ['UniProtKB'], 'identifier': ['P00533']}, {'resource': ['UniProt Accession'], 'identifier': ['EGFR_HUMAN']}]}], 'synonyms': [{'synonym': ['2.7.10.1', 'ERBB', 'ERBB1', 'HER1', 'Proto-oncogene c-ErbB-1', 'Receptor tyrosine-protein kinase erbB-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0001530|Epidermal growth factor receptor\nMRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV\nVLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA\nVLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF\nQNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC\nTGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV\nVTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK\nNCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF\nENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL\nFGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN\nLLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM\nGENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV\nALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS\nGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI\nCLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA\nRNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY\nGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK\nFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ\nQGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED\nSIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN\nTVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV\nAPQSSEFIGA'], 'gene-sequence': ['>lcl|BSEQ0019007|Epidermal growth factor receptor (EGFR)\nATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCG\nGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAG\nTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTG\nGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAG\nACCATCCAGGAGGTGGCTGGTTATGTCCTCATTGCCCTCAACACAGTGGAGCGAATTCCT\nTTGGAAAACCTGCAGATCATCAGAGGAAATATGTACTACGAAAATTCCTATGCCTTAGCA\nGTCTTATCTAACTATGATGCAAATAAAACCGGACTGAAGGAGCTGCCCATGAGAAATTTA\nCAGGAAATCCTGCATGGCGCCGTGCGGTTCAGCAACAACCCTGCCCTGTGCAACGTGGAG\nAGCATCCAGTGGCGGGACATAGTCAGCAGTGACTTTCTCAGCAACATGTCGATGGACTTC\nCAGAACCACCTGGGCAGCTGCCAAAAGTGTGATCCAAGCTGTCCCAATGGGAGCTGCTGG\nGGTGCAGGAGAGGAGAACTGCCAGAAACTGACCAAAATCATCTGTGCCCAGCAGTGCTCC\nGGGCGCTGCCGTGGCAAGTCCCCCAGTGACTGCTGCCACAACCAGTGTGCTGCAGGCTGC\nACAGGCCCCCGGGAGAGCGACTGCCTGGTCTGCCGCAAATTCCGAGACGAAGCCACGTGC\nAAGGACACCTGCCCCCCACTCATGCTCTACAACCCCACCACGTACCAGATGGATGTGAAC\nCCCGAGGGCAAATACAGCTTTGGTGCCACCTGCGTGAAGAAGTGTCCCCGTAATTATGTG\nGTGACAGATCACGGCTCGTGCGTCCGAGCCTGTGGGGCCGACAGCTATGAGATGGAGGAA\nGACGGCGTCCGCAAGTGTAAGAAGTGCGAAGGGCCTTGCCGCAAAGTGTGTAACGGAATA\nGGTATTGGTGAATTTAAAGACTCACTCTCCATAAATGCTACGAATATTAAACACTTCAAA\nAACTGCACCTCCATCAGTGGCGATCTCCACATCCTGCCGGTGGCATTTAGGGGTGACTCC\nTTCACACATACTCCTCCTCTGGATCCACAGGAACTGGATATTCTGAAAACCGTAAAGGAA\nATCACAGGGTTTTTGCTGATTCAGGCTTGGCCTGAAAACAGGACGGACCTCCATGCCTTT\nGAGAACCTAGAAATCATACGCGGCAGGACCAAGCAACATGGTCAGTTTTCTCTTGCAGTC\nGTCAGCCTGAACATAACATCCTTGGGATTACGCTCCCTCAAGGAGATAAGTGATGGAGAT\nGTGATAATTTCAGGAAACAAAAATTTGTGCTATGCAAATACAATAAACTGGAAAAAACTG\nTTTGGGACCTCCGGTCAGAAAACCAAAATTATAAGCAACAGAGGTGAAAACAGCTGCAAG\nGCCACAGGCCAGGTCTGCCATGCCTTGTGCTCCCCCGAGGGCTGCTGGGGCCCGGAGCCC\nAGGGACTGCGTCTCTTGCCGGAATGTCAGCCGAGGCAGGGAATGCGTGGACAAGTGCAAC\nCTTCTGGAGGGTGAGCCAAGGGAGTTTGTGGAGAACTCTGAGTGCATACAGTGCCACCCA\nGAGTGCCTGCCTCAGGCCATGAACATCACCTGCACAGGACGGGGACCAGACAACTGTATC\nCAGTGTGCCCACTACATTGACGGCCCCCACTGCGTCAAGACCTGCCCGGCAGGAGTCATG\nGGAGAAAACAACACCCTGGTCTGGAAGTACGCAGACGCCGGCCATGTGTGCCACCTGTGC\nCATCCAAACTGCACCTACGGATGCACTGGGCCAGGTCTTGAAGGCTGTCCAACGAATGGG\nCCTAAGATCCCGTCCATCGCCACTGGGATGGTGGGGGCCCTCCTCTTGCTGCTGGTGGTG\nGCCCTGGGGATCGGCCTCTTCATGCGAAGGCGCCACATCGTTCGGAAGCGCACGCTGCGG\nAGGCTGCTGCAGGAGAGGGAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAAC\nCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGCTCC\nGGTGCGTTCGGCACGGTGTATAAGGGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATT\nCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTC\nGATGAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATC\nTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTTCGGCTGCCTCCTGGAC\nTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAG\nATCGCAAAGGGCATGAACTACTTGGAGGACCGTCGCTTGGTGCACCGCGACCTGGCAGCC\nAGGAACGTACTGGTGAAAACACCGCAGCATGTCAAGATCACAGATTTTGGGCTGGCCAAA\nCTGCTGGGTGCGGAAGAGAAAGAATACCATGCAGAAGGAGGCAAAGTGCCTATCAAGTGG\nATGGCATTGGAATCAATTTTACACAGAATCTATACCCACCAGAGTGATGTCTGGAGCTAC\nGGGGTGACCGTTTGGGAGTTGATGACCTTTGGATCCAAGCCATATGACGGAATCCCTGCC\nAGCGAGATCTCCTCCATCCTGGAGAAAGGAGAACGCCTCCCTCAGCCACCCATATGTACC\nATCGATGTCTACATGATCATGGTCAAGTGCTGGATGATAGACGCAGATAGTCGCCCAAAG\nTTCCGTGAGTTGATCATCGAATTCTCCAAAATGGCCCGAGACCCCCAGCGCTACCTTGTC\nATTCAGGGGGATGAAAGAATGCATTTGCCAAGTCCTACAGACTCCAACTTCTACCGTGCC\nCTGATGGATGAAGAAGACATGGACGACGTGGTGGATGCCGACGAGTACCTCATCCCACAG\nCAGGGCTTCTTCAGCAGCCCCTCCACGTCACGGACTCCCCTCCTGAGCTCTCTGAGTGCA\nACCAGCAACAATTCCACCGTGGCTTGCATTGATAGAAATGGGCTGCAAAGCTGTCCCATC\nAAGGAAGACAGCTTCTTGCAGCGATACAGCTCAGACCCCACAGGCGCCTTGACTGAGGAC\nAGCATAGACGACACCTTCCTCCCAGTGCCTGAATACATAAACCAGTCCGTTCCCAAAAGG\nCCCGCTGGCTCTGTGCAGAATCCTGTCTATCACAATCAGCCTCTGAACCCCGCGCCCAGC\nAGAGACCCACACTACCAGGACCCCCACAGCACTGCAGTGGGCAACCCCGAGTATCTCAAC\nACTGTCCAGCCCACCTGTGTCAACAGCACATTCGACAGCCCTGCCCACTGGGCCCAGAAA\nGGCAGCCACCAAATTAGCCTGGACAACCCTGACTACCAGCAGGACTTCTTTCCCAAGGAA\nGCCAAGCCAAATGGCATCTTTAAGGGCTCCACAGCTGAAAATGCAGAATACCTAAGGGTC\nGCGCCACAAAGCAGTGAATTTATTGGAGCATGA'], 'pfams': [{'pfam': [{'identifier': ['PF07714'], 'name': ['PK_Tyr_Ser-Thr']}, {'identifier': ['PF00757'], 'name': ['Furin-like']}, {'identifier': ['PF01030'], 'name': ['Recep_L_domain']}, {'identifier': ['PF14843'], 'name': ['GF_recep_IV']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['basolateral plasma membrane']}, {'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['endocytic vesicle']}, {'category': ['component'], 'description': ['endoplasmic reticulum membrane']}, {'category': ['component'], 'description': ['endosome']}, {'category': ['component'], 'description': ['endosome membrane']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['focal adhesion']}, {'category': ['component'], 'description': ['Golgi membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['multivesicular body, internal vesicle lumen']}, {'category': ['component'], 'description': ['nuclear membrane']}, {'category': ['component'], 'description': ['nucleus']}, {'category': ['component'], 'description': ['perinuclear region of cytoplasm']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['receptor complex']}, {'category': ['component'], 'description': ['Shc-EGFR complex']}, {'category': ['function'], 'description': ['actin filament binding']}, {'category': ['function'], 'description': ['ATP binding']}, {'category': ['function'], 'description': ['chromatin binding']}, {'category': ['function'], 'description': ['double-stranded DNA binding']}, {'category': ['function'], 'description': ['enzyme binding']}, {'category': ['function'], 'description': ['epidermal growth factor-activated receptor activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['MAP kinase kinase kinase activity']}, {'category': ['function'], 'description': ['protein heterodimerization activity']}, {'category': ['function'], 'description': ['protein phosphatase binding']}, {'category': ['function'], 'description': ['protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['receptor signaling protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['transmembrane receptor protein tyrosine kinase activity']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['function'], 'description': ['ubiquitin protein ligase binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation of phospholipase A2 activity by calcium-mediated signaling']}, {'category': ['process'], 'description': ['activation of phospholipase C activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to epidermal growth factor stimulus']}, {'category': ['process'], 'description': ['cellular response to estradiol stimulus']}, {'category': ['process'], 'description': ['cerebral cortex cell migration']}, {'category': ['process'], 'description': ['digestive tract morphogenesis']}, {'category': ['process'], 'description': ['embryonic placenta development']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['hair follicle development']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['learning or memory']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['morphogenesis of an epithelial fold']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['negative regulation of epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of protein catabolic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['ossification']}, {'category': ['process'], 'description': ['peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['phosphatidylinositol-mediated signaling']}, {'category': ['process'], 'description': ['positive regulation of catenin import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of cell migration']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle']}, {'category': ['process'], 'description': ['positive regulation of DNA repair']}, {'category': ['process'], 'description': ['positive regulation of DNA replication']}, {'category': ['process'], 'description': ['positive regulation of epithelial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['protein autophosphorylation']}, {'category': ['process'], 'description': ['protein insertion into membrane']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of nitric-oxide synthase activity']}, {'category': ['process'], 'description': ['regulation of peptidyl-tyrosine phosphorylation']}, {'category': ['process'], 'description': ['response to stress']}, {'category': ['process'], 'description': ['response to UV-A']}, {'category': ['process'], 'description': ['salivary gland morphogenesis']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['single organismal cell-cell adhesion']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11'], 'pubmed-id': ['16336752'], 'citation': ['Snyder LC, Astsaturov I, Weiner LM: Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer. Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S71-80.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0002094'], 'name': ['Complement C1q subcomponent subunit A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit A'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QA'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['9.45'], 'molecular-weight': ['26016.47'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1241']}, {'resource': ['GenAtlas'], 'identifier': ['C1QA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF135157']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4894854']}, {'resource': ['UniProtKB'], 'identifier': ['P02745']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QA_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit A precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA'], 'gene-sequence': ['>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002095'], 'name': ['Complement C1q subcomponent subunit B'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit B'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QB'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-27'], 'theoretical-pi': ['8.87'], 'molecular-weight': ['26721.62'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1242']}, {'resource': ['GenAtlas'], 'identifier': ['C1QB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03084']}, {'resource': ['GenBank Protein Database'], 'identifier': ['573114']}, {'resource': ['UniProtKB'], 'identifier': ['P02746']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QB_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit B precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA'], 'gene-sequence': ['>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear development']}]}]}]}, {'id': ['BE0002096'], 'name': ['Complement C1q subcomponent subunit C'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202103'], 'pubmed-id': ['32117299'], 'citation': ['Deveuve Q, Lajoie L, Barrault B, Thibault G: The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass. Front Immunol. 2020 Feb 11;11:168. doi: 10.3389/fimmu.2020.00168. eCollection 2020.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit C'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QC'], 'locus': ['1p36.11'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['25773.56'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1245']}, {'resource': ['GenAtlas'], 'identifier': ['C1QC']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF087892']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33150626']}, {'resource': ['UniProtKB'], 'identifier': ['P02747']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QC_HUMAN']}]}], 'synonyms': [{'synonym': ['C1QG']}], 'amino-acid-sequence': ['>lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD'], 'gene-sequence': ['>lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['negative regulation of granulocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of macrophage differentiation']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13078'], 'pubmed-id': ['17704420'], 'citation': ['Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13079'], 'pubmed-id': ['7547242'], 'citation': [""Negri DR, Tosi E, Valota O, Ferrini S, Cambiaggi A, Sforzini S, Silvani A, Ruffini PA, Colnaghi MI, Canevari S: In vitro and in vivo stability and anti-tumour efficacy of an anti-EGFR/anti-CD3 F(ab')2 bispecific monoclonal antibody. Br J Cancer. 1995 Oct;72(4):928-33.""]}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1713'], 'pubmed-id': ['17139284'], 'citation': ['Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.']}, {'ref-id': ['A1715'], 'pubmed-id': ['17016423'], 'citation': ['Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.']}, {'ref-id': ['A13078'], 'pubmed-id': ['17704420'], 'citation': ['Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}]}]"
"['DB00003', 'BTD00001', 'BIOD00001']",['Dornase alfa'],biotech,"['Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is identical to the endogenous human enzyme. Dornase alfa cleaves extracellular DNA to 5-phosphodinucleotide and 5-phosphooligonucleotide end products without affecting intracellular DNA. In individuals with cystic fibrosis, extracellular DNA, which is an extremely viscous anion, is released by degenerating leukocytes that accumulate during inflammatory responses to infections. Enzymatic breakdown of this extracellular DNA appears to reduce sputum viscosity and viscoelasticity.']",['liquid'],['Used as adjunct therapy in the treatment of cystic fibrosis. '],"['Dornase alfa is a biosynthetic form of human DNase I. The enzyme is involved in endonucleolytic cleavage of extracellular DNA to 5-phosphodinucleotide and 5-phosphooligonucleotide end products. It has no effect on intracellular DNA. Optimal activity is dependent on the presence of divalent cations such as calcium and magnesium. Extracellular DNA is a viscous anionic polymer and its breakdown appears to improve the viscosity and viscoelasticity of purulent sputum of individuals with CF, thus reducing airflow obstruction. Dornase alfa does not seem to have any effect on non-purulent sputum.']",[None],"[{'target': [{'id': ['BE0004796'], 'name': ['DNA'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A12'], 'pubmed-id': ['8792953'], 'citation': ['Cramer GW, Bosso JA: The role of dornase alfa in the treatment of cystic fibrosis. Ann Pharmacother. 1996 Jun;30(6):656-61.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes']}]}]"
"['DB00004', 'BTD00084', 'BIOD00084']",['Denileukin diftitox'],biotech,['A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.'],['liquid'],['For treatment of cutaneous T-cell lymphoma'],['Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.'],[None],"[{'target': [{'id': ['BE0000658'], 'name': ['Interleukin-2 receptor subunit alpha'], 'organism': ['Humans'], 'actions': [{'action': ['binder']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1717'], 'pubmed-id': ['2786749'], 'citation': ['Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res. 1989 Jul 15;49(14):4042-6.']}, {'ref-id': ['A1719'], 'pubmed-id': ['3124610'], 'citation': ['Murphy JR, Kelley VE, Strom TB: Interleukin 2 toxin: a step toward selective immunomodulation. Am J Kidney Dis. 1988 Feb;11(2):159-62.']}, {'ref-id': ['A1721'], 'pubmed-id': ['18684057'], 'citation': ['Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.']}, {'ref-id': ['A15'], 'pubmed-id': ['17187516'], 'citation': ['Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit alpha'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T cells.'], 'gene-name': ['IL2RA'], 'locus': ['10p15-p14'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-259'], 'signal-regions': ['1-21'], 'theoretical-pi': ['6.49'], 'molecular-weight': ['30818.915'], 'chromosome-location': ['10'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6008']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01057']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33813']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['1695']}, {'resource': ['UniProtKB'], 'identifier': ['P01589']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RA_HUMAN']}]}], 'synonyms': [{'synonym': ['IL-2 receptor subunit alpha', 'p55', 'TAC antigen']}], 'amino-acid-sequence': ['>lcl|BSEQ0018991|Interleukin-2 receptor subunit alpha\nMDSYLLMWGLLTFIMVPGCQAELCDDDPPEIPHATFKAMAYKEGTMLNCECKRGFRRIKS\nGSLYMLCTGNSSHSSWDNQCQCTSSATRNTTKQVTPQPEEQKERKTTEMQSPMQPVDQAS\nLPGHCREPPPWENEATERIYHFVVGQMVYYQCVQGYRALHRGPAESVCKMTHGKTRWTQP\nQLICTGEMETSQFPGEEKPQASPEGRPESETSCLVTTTDFQIQTEMAATMETSIFTTEYQ\nVAVAGCVFLLISVLLLSGLTWQRRQRKSRRTI'], 'gene-sequence': ['>lcl|BSEQ0018992|Interleukin-2 receptor subunit alpha (IL2RA)\nATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAG\nGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCC\nTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGC\nGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGT\nCAATGCACAAGCTCTGCCACTCGGAACACAACGAAACAAGTGACACCTCAACCTGAAGAA\nCAGAAAGAAAGGAAAACCACAGAAATGCAAAGTCCAATGCAGCCAGTGGACCAAGCGAGC\nCTTCCAGGTCACTGCAGGGAACCTCCACCATGGGAAAATGAAGCCACAGAGAGAATTTAT\nCATTTCGTGGTGGGGCAGATGGTTTATTATCAGTGCGTCCAGGGATACAGGGCTCTACAC\nAGAGGTCCTGCTGAGAGCGTCTGCAAAATGACCCACGGGAAGACAAGGTGGACCCAGCCC\nCAGCTCATATGCACAGGTGAAATGGAGACCAGTCAGTTTCCAGGTGAAGAGAAGCCTCAG\nGCAAGCCCCGAAGGCCGTCCTGAGAGTGAGACTTCCTGCCTCGTCACAACAACAGATTTT\nCAAATACAGACAGAAATGGCTGCAACCATGGAGACGTCCATATTTACAACAGAGTACCAG\nGTAGCAGTGGCCGGCTGTGTTTTCCTGCTGATCAGCGTCCTCCTCCTGAGTGGGCTCACC\nTGGCAGCGGAGACAGAGGAAGAGTAGAAGAACAATCTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00084'], 'name': ['Sushi']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['drug binding']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['activation-induced cell death of T cells']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cell proliferation']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of defense response to virus']}, {'category': ['process'], 'description': ['negative regulation of immune response']}, {'category': ['process'], 'description': ['negative regulation of inflammatory response']}, {'category': ['process'], 'description': ['negative regulation of T cell proliferation']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Notch signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of activated T cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of T cell differentiation']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['regulation of T cell homeostatic proliferation']}, {'category': ['process'], 'description': ['regulation of T cell tolerance induction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}]}]}]}, {'id': ['BE0000651'], 'name': ['Interleukin-2 receptor subunit beta'], 'organism': ['Humans'], 'actions': [{'action': ['agonist']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13080'], 'pubmed-id': ['15811959'], 'citation': ['Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.']}, {'ref-id': ['A13081'], 'pubmed-id': ['16516670'], 'citation': ['Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.']}, {'ref-id': ['A1721'], 'pubmed-id': ['18684057'], 'citation': ['Duvic M, Talpur R: Optimizing denileukin diftitox (Ontak) therapy. Future Oncol. 2008 Aug;4(4):457-69. doi: 10.2217/14796694.4.4.457.']}, {'ref-id': ['A15'], 'pubmed-id': ['17187516'], 'citation': ['Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Interleukin-2 receptor subunit beta'], 'general-function': ['Interleukin-2 receptor activity'], 'specific-function': ['Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2.'], 'gene-name': ['IL2RB'], 'locus': ['22q13|22q13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['241-265'], 'signal-regions': ['1-26'], 'theoretical-pi': ['4.68'], 'molecular-weight': ['61116.59'], 'chromosome-location': ['22'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6009']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M26062']}, {'resource': ['GenBank Protein Database'], 'identifier': ['307048']}, {'resource': ['UniProtKB'], 'identifier': ['P14784']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RB_HUMAN']}]}], 'synonyms': [{'synonym': ['High affinity IL-2 receptor subunit beta', 'IL-2 receptor subunit beta', 'p70-75', 'p75']}], 'amino-acid-sequence': ['>lcl|BSEQ0016166|Interleukin-2 receptor subunit beta\nMAAPALSWRLPLLILLLPLATSWASAAVNGTSQFTCFYNSRANISCVWSQDGALQDTSCQ\nVHAWPDRRRWNQTCELLPVSQASWACNLILGAPDSQKLTTVDIVTLRVLCREGVRWRVMA\nIQDFKPFENLRLMAPISLQVVHVETHRCNISWEISQASHYFERHLEFEARTLSPGHTWEE\nAPLLTLKQKQEWICLETLTPDTQYEFQVRVKPLQGEFTTWSPWSQPLAFRTKPAALGKDT\nIPWLGHLLVGLSGAFGFIILVYLLINCRNTGPWLKKVLKCNTPDPSKFFSQLSSEHGGDV\nQKWLSSPFPSSSFSPGGLAPEISPLEVLERDKVTQLLLQQDKVPEPASLSSNHSLTSCFT\nNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAPTGSSPQPLQPLSGEDDAYCT\nFPSRDDLLLFSPSLLGGPSPPSTAPGGSGAGEERMPPSLQERVPRDWDPQPLGPPTPGVP\nDLVDFQPPPELVLREAGEEVPDAGPREGVSFPWSRPPGQGEFRALNARLPLNTDAYLSLQ\nELQGQDPTHLV'], 'gene-sequence': ['>lcl|BSEQ0016167|Interleukin-2 receptor subunit beta (IL2RB)\nATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCT\nACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCG\nAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAA\nGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGT\nCAAGCATCCTGGGCCTGCAACCTGATCCTCGGAGCCCCAGATTCTCAGAAACTGACCACA\nGTTGACATCGTCACCCTGAGGGTGCTGTGCCGTGAGGGGGTGCGATGGAGGGTGATGGCC\nATCCAGGACTTCAAGCCCTTTGAGAACCTTCGCCTGATGGCCCCCATCTCCCTCCAAGTT\nGTCCACGTGGAGACCCACAGATGCAACATAAGCTGGGAAATCTCCCAAGCCTCCCACTAC\nTTTGAAAGACACCTGGAGTTCGAGGCCCGGACGCTGTCCCCAGGCCACACCTGGGAGGAG\nGCCCCCCTGCTGACTCTCAAGCAGAAGCAGGAATGGATCTGCCTGGAGACGCTCACCCCA\nGACACCCAGTATGAGTTTCAGGTGCGGGTCAAGCCTCTGCAAGGCGAGTTCACGACCTGG\nAGCCCCTGGAGCCAGCCCCTGGCCTTCAGGACAAAGCCTGCAGCCCTTGGGAAGGACACC\nATTCCGTGGCTCGGCCACCTCCTCGTGGGCCTCAGCGGGGCTTTTGGCTTCATCATCTTA\nGTGTACTTGCTGATCAACTGCAGGAACACCGGGCCATGGCTGAAGAAGGTCCTGAAGTGT\nAACACCCCAGACCCCTCGAAGTTCTTTTCCCAGCTGAGCTCAGAGCATGGAGGAGACGTC\nCAGAAGTGGCTCTCTTCGCCCTTCCCCTCATCGTCCTTCAGCCCTGGCGGCCTGGCACCT\nGAGATCTCGCCACTAGAAGTGCTGGAGAGGGACAAGGTGACGCAGCTGCTCCTGCAGCAG\nGACAAGGTGCCTGAGCCCGCATCCTTAAGCAGCAACCACTCGCTGACCAGCTGCTTCACC\nAACCAGGGTTACTTCTTCTTCCACCTCCCGGATGCCTTGGAGATAGAGGCCTGCCAGGTG\nTACTTTACTTACGACCCCTACTCAGAGGAAGACCCTGATGAGGGTGTGGCCGGGGCACCC\nACAGGGTCTTCCCCCCAACCCCTGCAGCCTCTGTCAGGGGAGGACGACGCCTACTGCACC\nTTCCCCTCCAGGGATGACCTGCTGCTCTTCTCCCCCAGTCTCCTCGGTGGCCCCAGCCCC\nCCAAGCACTGCCCCTGGGGGCAGTGGGGCCGGTGAAGAGAGGATGCCCCCTTCTTTGCAA\nGAAAGAGTCCCCAGAGACTGGGACCCCCAGCCCCTGGGGCCTCCCACCCCAGGAGTCCCA\nGACCTGGTGGATTTTCAGCCACCCCCTGAGCTGGTGCTGCGAGAGGCTGGGGAGGAGGTC\nCCTGACGCTGGCCCCAGGGAGGGAGTCAGTTTCCCCTGGTCCAGGCCTCCTGGGCAGGGG\nGAGTTCAGGGCCCTTAATGCTCGCCTGCCCCTGAACACTGATGCCTACTTGTCCCTCCAA\nGAACTCCAGGGTCAGGACCCAACTCACTTGGTGTAG'], 'pfams': [None], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['function'], 'description': ['interleukin-2 receptor activity']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['negative regulation of apoptotic process']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['protein complex assembly']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002102'], 'name': ['Cytokine receptor common subunit gamma'], 'organism': ['Humans'], 'actions': [None], 'references': [{'articles': [{'article': [{'ref-id': ['A13080'], 'pubmed-id': ['15811959'], 'citation': ['Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2005 Jul 15;106(2):454-7. Epub 2005 Apr 5.']}, {'ref-id': ['A13081'], 'pubmed-id': ['16516670'], 'citation': ['Foss F: Clinical experience with denileukin diftitox (ONTAK). Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6.']}, {'ref-id': ['A13082'], 'pubmed-id': ['11707860'], 'citation': ['Foss FM: DAB(389)IL-2 (denileukin diftitox, ONTAK): a new fusion protein technology. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Cytokine receptor common subunit gamma'], 'general-function': ['Interleukin-2 binding'], 'specific-function': ['Common subunit for the receptors for a variety of interleukins.'], 'gene-name': ['IL2RG'], 'locus': ['Xq13.1'], 'cellular-location': ['Membrane'], 'transmembrane-regions': ['263-283'], 'signal-regions': ['1-22'], 'theoretical-pi': ['6.31'], 'molecular-weight': ['42286.68'], 'chromosome-location': ['X'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6010']}, {'resource': ['GenAtlas'], 'identifier': ['IL2RG']}, {'resource': ['GenBank Gene Database'], 'identifier': ['D11086']}, {'resource': ['GenBank Protein Database'], 'identifier': ['219890']}, {'resource': ['UniProtKB'], 'identifier': ['P31785']}, {'resource': ['UniProt Accession'], 'identifier': ['IL2RG_HUMAN']}]}], 'synonyms': [{'synonym': ['gammaC', 'IL-2 receptor subunit gamma', 'IL-2R subunit gamma', 'IL-2RG', 'Interleukin-2 receptor subunit gamma', 'p64']}], 'amino-acid-sequence': ['>lcl|BSEQ0004122|Cytokine receptor common subunit gamma\nMLKPSLPFTSLLFLQLPLLGVGLNTTILTPNGNEDTTADFFLTTMPTDSLSVSTLPLPEV\nQCFVFNVEYMNCTWNSSSEPQPTNLTLHYWYKNSDNDKVQKCSHYLFSEEITSGCQLQKK\nEIHLYQTFVVQLQDPREPRRQATQMLKLQNLVIPWAPENLTLHKLSESQLELNWNNRFLN\nHCLEHLVQYRTDWDHSWTEQSVDYRHKFSLPSVDGQKRYTFRVRSRFNPLCGSAQHWSEW\nSHPIHWGSNTSKENPFLFALEAVVISVGSMGLIISLLCVYFWLERTMPRIPTLKNLEDLV\nTEYHGNFSAWSGVSKGLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSPYWAP\nPCYTLKPET'], 'gene-sequence': ['>lcl|BSEQ0016682|Cytokine receptor common subunit gamma (IL2RG)\nATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGA\nGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTC\nTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTT\nCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCC\nCAGCCTACCAACCTCACTCTGCATTATTGGTACAAGAACTCGGATAATGATAAAGTCCAG\nAAGTGCAGCCACTATCTATTCTCTGAAGAAATCACTTCTGGCTGTCAGTTGCAAAAAAAG\nGAGATCCACCTCTACCAAACATTTGTTGTTCAGCTCCAGGACCCACGGGAACCCAGGAGA\nCAGGCCACACAGATGCTAAAACTGCAGAATCTGGTGATCCCCTGGGCTCCAGAGAACCTA\nACACTTCACAAACTGAGTGAATCCCAGCTAGAACTGAACTGGAACAACAGATTCTTGAAC\nCACTGTTTGGAGCACTTGGTGCAGTACCGGACTGACTGGGACCACAGCTGGACTGAACAA\nTCAGTGGATTATAGACATAAGTTCTCCTTGCCTAGTGTGGATGGGCAGAAACGCTACACG\nTTTCGTGTTCGGAGCCGCTTTAACCCACTCTGTGGAAGTGCTCAGCATTGGAGTGAATGG\nAGCCACCCAATCCACTGGGGGAGCAATACTTCAAAAGAGAATCCTTTCCTGTTTGCATTG\nGAAGCCGTGGTTATCTCTGTTGGCTCCATGGGATTGATTATCAGCCTTCTCTGTGTGTAT\nTTCTGGCTGGAACGGACGATGCCCCGAATTCCCACCCTGAAGAACCTAGAGGATCTTGTT\nACTGAATACCACGGGAACTTTTCGGCCTGGAGTGGTGTGTCTAAGGGACTGGCTGAGAGT\nCTGCAGCCAGACTACAGTGAACGACTCTGCCTCGTCAGTGAGATTCCCCCAAAAGGAGGG\nGCCCTTGGGGAGGGGCCTGGGGCCTCCCCATGCAACCAGCATAGCCCCTACTGGGCCCCC\nCCATGTTACACCCTAAAGCCTGAAACCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00041'], 'name': ['fn3']}, {'identifier': ['PF09240'], 'name': ['IL6Ra-bind']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['intracellular']}, {'category': ['component'], 'description': ['membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['cytokine receptor activity']}, {'category': ['function'], 'description': ['interleukin-2 binding']}, {'category': ['process'], 'description': ['activation of MAPKK activity']}, {'category': ['process'], 'description': ['axon guidance']}, {'category': ['process'], 'description': ['epidermal growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['Fc-epsilon receptor signaling pathway']}, {'category': ['process'], 'description': ['fibroblast growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['insulin receptor signaling pathway']}, {'category': ['process'], 'description': ['interleukin-2-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-4-mediated signaling pathway']}, {'category': ['process'], 'description': ['interleukin-7-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['neurotrophin TRK receptor signaling pathway']}, {'category': ['process'], 'description': ['Ras protein signal transduction']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['small GTPase mediated signal transduction']}, {'category': ['process'], 'description': ['vascular endothelial growth factor receptor signaling pathway']}, {'category': ['process'], 'description': ['viral process']}]}]}]}]}]"
"['DB00005', 'BTD00052', 'BIOD00052']",['Etanercept'],biotech,"['Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA).']",['liquid'],"['Etanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and in chronic moderate to severe plaque psoriasis in patients 4 years of age and older.[L14862,L45523] It is also used to manage signs and symptoms of polyarticular idiopathic arthritis and Juvenile Psoriatic Arthritis in those aged 2 years and older. Etanercept is also used to manage the symptoms of psoriatic arthritis and ankylosing spondylitis.[L48526] ']","['There are two distinct receptors for TNF (TNFRs), a 55 kilodalton protein (p55) and a 75 kilodalton protein (p75). The biological activity of TNF is dependent upon binding to either cell surface receptor (p75 or p55).[A216522] Etanercept is a dimeric soluble form of the p75 TNF receptor that can bind to two TNF molecules, thereby effectively removing them from circulation. Notably, etancerpt is only capable of binding to the active trimeric form of TNF as its binding site is located in the cleft between subunits.[A77626]TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.[A216522] Increased levels of TNF are found in tissues and fluids of those with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. ']",[None],"[{'target': [{'id': ['BE0000704'], 'name': ['Tumor necrosis factor'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor', 'antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1723'], 'pubmed-id': ['10206649'], 'citation': ['Park YC, Burkitt V, Villa AR, Tong L, Wu H: Structural basis for self-association and receptor recognition of human TRAF2. Nature. 1999 Apr 8;398(6727):533-8.']}, {'ref-id': ['A1725'], 'pubmed-id': ['10338381'], 'citation': ['Sandborn WJ, Hanauer SB: Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999 May;5(2):119-33.']}, {'ref-id': ['A1727'], 'pubmed-id': ['10357816'], 'citation': ['Grell M, Zimmermann G, Gottfried E, Chen CM, Grunwald U, Huang DC, Wu Lee YH, Durkop H, Engelmann H, Scheurich P, Wajant H, Strasser A: Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO J. 1999 Jun 1;18(11):3034-43.']}, {'ref-id': ['A1729'], 'pubmed-id': ['10375846'], 'citation': ['Moreland LW: Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. Cleve Clin J Med. 1999 Jun;66(6):367-74.']}, {'ref-id': ['A1731'], 'pubmed-id': ['10405518'], 'citation': ['Calabrese LH: Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. J Am Osteopath Assoc. 1999 Jun;99(6):313-21.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}, {'ref-id': ['A247970'], 'pubmed-id': ['31092047'], 'citation': ['Clark IA, Vissel B: Neurodegenerative disease treatments by direct TNF reduction, SB623 cells, maraviroc and irisin and MCC950, from an inflammatory perspective - a Commentary. Expert Rev Neurother. 2019 Jun;19(6):535-543. doi: 10.1080/14737175.2019.1618710. Epub 2019 May 24.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Tumor necrosis factor'], 'general-function': ['Tumor necrosis factor receptor binding'], 'specific-function': [""Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Upregulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective (PubMed:23396208). Key mediator of cell death in the anticancer action of BCG-stimulated neutrophils in combination with DIABLO/SMAC mimetic in the RT4v6 bladder cancer cell line (PubMed:22517918).The TNF intracellular domain (ICD) form induces IL12 production in dendritic cells.""], 'gene-name': ['TNF'], 'locus': ['6p21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['36-56'], 'signal-regions': [None], 'theoretical-pi': ['6.92'], 'molecular-weight': ['25644.15'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:11892']}, {'resource': ['GenAtlas'], 'identifier': ['TNF']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M16441']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339741']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2635']}, {'resource': ['UniProtKB'], 'identifier': ['P01375']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFA_HUMAN']}]}], 'synonyms': [{'synonym': ['Cachectin', 'TNF-a', 'TNF-alpha', 'TNFA', 'TNFSF2', 'Tumor necrosis factor ligand superfamily member 2']}], 'amino-acid-sequence': ['>lcl|BSEQ0001404|Tumor necrosis factor\nMSTESMIRDVELAEEALPKKTGGPQGSRRCLFLSLFSFLIVAGATTLFCLLHFGVIGPQR\nEEFPRDLSLISPLAQAVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELR\nDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRE\nTPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIAL'], 'gene-sequence': ['>lcl|BSEQ0021837|Tumor necrosis factor (TNF)\nATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAG\nACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATC\nGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGG\nGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCT\nTCTCGAACCCCGAGTGACAAGCCTGTAGCCCATGTTGTAGCAAACCCTCAAGCTGAGGGG\nCAGCTCCAGTGGCTGAACCGCCGGGCCAATGCCCTCCTGGCCAATGGCGTGGAGCTGAGA\nGATAACCAGCTGGTGGTGCCATCAGAGGGCCTGTACCTCATCTACTCCCAGGTCCTCTTC\nAAGGGCCAAGGCTGCCCCTCCACCCATGTGCTCCTCACCCACACCATCAGCCGCATCGCC\nGTCTCCTACCAGACCAAGGTCAACCTCCTCTCTGCCATCAAGAGCCCCTGCCAGAGGGAG\nACCCCAGAGGGGGCTGAGGCCAAGCCCTGGTATGAGCCCATCTATCTGGGAGGGGTCTTC\nCAGCTGGAGAAGGGTGACCGACTCAGCGCTGAGATCAATCGGCCCGACTATCTCGACTTT\nGCCGAGTCTGGGCAGGTCTACTTTGGGATCATTGCCCTGTGA'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cell surface']}, {'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['integral component of plasma membrane']}, {'category': ['component'], 'description': ['membrane raft']}, {'category': ['component'], 'description': ['phagocytic cup']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['component'], 'description': ['recycling endosome']}, {'category': ['function'], 'description': ['cytokine activity']}, {'category': ['function'], 'description': ['identical protein binding']}, {'category': ['function'], 'description': ['protease binding']}, {'category': ['function'], 'description': ['transcription regulatory region DNA binding']}, {'category': ['function'], 'description': ['tumor necrosis factor receptor binding']}, {'category': ['process'], 'description': ['activation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['activation of MAPK activity']}, {'category': ['process'], 'description': ['activation of MAPKKK activity']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular response to amino acid stimulus']}, {'category': ['process'], 'description': ['cellular response to nicotine']}, {'category': ['process'], 'description': ['cellular response to organic cyclic compound']}, {'category': ['process'], 'description': ['chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['cortical actin cytoskeleton organization']}, {'category': ['process'], 'description': ['death-inducing signaling complex assembly']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['embryonic digestive tract development']}, {'category': ['process'], 'description': ['epithelial cell proliferation involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['establishment of protein localization to plasma membrane']}, {'category': ['process'], 'description': ['extracellular matrix organization']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway']}, {'category': ['process'], 'description': ['extrinsic apoptotic signaling pathway via death domain receptors']}, {'category': ['process'], 'description': ['glucose metabolic process']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['inflammatory response']}, {'category': ['process'], 'description': ['intrinsic apoptotic signaling pathway in response to DNA damage']}, {'category': ['process'], 'description': ['JNK cascade']}, {'category': ['process'], 'description': ['leukocyte tethering or rolling']}, {'category': ['process'], 'description': ['lipopolysaccharide-mediated signaling pathway']}, {'category': ['process'], 'description': ['MAPK cascade']}, {'category': ['process'], 'description': ['necroptotic signaling pathway']}, {'category': ['process'], 'description': ['negative regulation of alkaline phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of bicellular tight junction assembly']}, {'category': ['process'], 'description': ['negative regulation of branching involved in lung morphogenesis']}, {'category': ['process'], 'description': ['negative regulation of cytokine secretion involved in immune response']}, {'category': ['process'], 'description': ['negative regulation of extrinsic apoptotic signaling pathway in absence of ligand']}, {'category': ['process'], 'description': ['negative regulation of fat cell differentiation']}, {'category': ['process'], 'description': ['negative regulation of gene expression']}, {'category': ['process'], 'description': ['negative regulation of glucose import']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['negative regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['negative regulation of lipid catabolic process']}, {'category': ['process'], 'description': ['negative regulation of lipid storage']}, {'category': ['process'], 'description': ['negative regulation of myoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of myosin-light-chain-phosphatase activity']}, {'category': ['process'], 'description': ['negative regulation of osteoblast differentiation']}, {'category': ['process'], 'description': ['negative regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['negative regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['negative regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['negative regulation of viral genome replication']}, {'category': ['process'], 'description': ['osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of calcidiol 1-monooxygenase activity']}, {'category': ['process'], 'description': ['positive regulation of cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of ceramide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine (C-X-C motif) ligand 2 production']}, {'category': ['process'], 'description': ['positive regulation of chemokine biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of chemokine production']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of cysteine-type endopeptidase activity involved in apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of cytokine production']}, {'category': ['process'], 'description': ['positive regulation of cytokine secretion']}, {'category': ['process'], 'description': ['positive regulation of ERK1 and ERK2 cascade']}, {'category': ['process'], 'description': ['positive regulation of fever generation']}, {'category': ['process'], 'description': ['positive regulation of gene expression']}, {'category': ['process'], 'description': ['positive regulation of hair follicle development']}, {'category': ['process'], 'description': ['positive regulation of heterotypic cell-cell adhesion']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-6 production']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of interleukin-8 production']}, {'category': ['process'], 'description': ['positive regulation of JUN kinase activity']}, {'category': ['process'], 'description': ['positive regulation of MAP kinase activity']}, {'category': ['process'], 'description': ['positive regulation of membrane protein ectodomain proteolysis']}, {'category': ['process'], 'description': ['positive regulation of mononuclear cell migration']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NF-kappaB transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of NFAT protein import into nucleus']}, {'category': ['process'], 'description': ['positive regulation of NIK/NF-kappaB signaling']}, {'category': ['process'], 'description': ['positive regulation of nitric oxide biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of osteoclast differentiation']}, {'category': ['process'], 'description': ['positive regulation of peptidyl-serine phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of phagocytosis']}, {'category': ['process'], 'description': ['positive regulation of podosome assembly']}, {'category': ['process'], 'description': ['positive regulation of programmed cell death']}, {'category': ['process'], 'description': ['positive regulation of protein complex assembly']}, {'category': ['process'], 'description': ['positive regulation of protein complex disassembly']}, {'category': ['process'], 'description': ['positive regulation of protein kinase activity']}, {'category': ['process'], 'description': ['positive regulation of protein kinase B signaling']}, {'category': ['process'], 'description': ['positive regulation of protein localization to cell surface']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of protein transport']}, {'category': ['process'], 'description': ['positive regulation of sequence-specific DNA binding transcription factor activity']}, {'category': ['process'], 'description': ['positive regulation of smooth muscle cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of transcription from RNA polymerase II promoter']}, {'category': ['process'], 'description': ['positive regulation of transcription, DNA-templated']}, {'category': ['process'], 'description': ['positive regulation of translational initiation by iron']}, {'category': ['process'], 'description': ['positive regulation of vitamin D biosynthetic process']}, {'category': ['process'], 'description': ['protein import into nucleus, translocation']}, {'category': ['process'], 'description': ['protein kinase B signaling']}, {'category': ['process'], 'description': ['receptor biosynthetic process']}, {'category': ['process'], 'description': ['regulation of branching involved in salivary gland morphogenesis']}, {'category': ['process'], 'description': ['regulation of establishment of endothelial barrier']}, {'category': ['process'], 'description': ['regulation of I-kappaB kinase/NF-kappaB signaling']}, {'category': ['process'], 'description': ['regulation of immunoglobulin secretion']}, {'category': ['process'], 'description': ['regulation of insulin secretion']}, {'category': ['process'], 'description': ['regulation of tumor necrosis factor-mediated signaling pathway']}, {'category': ['process'], 'description': ['response to glucocorticoid']}, {'category': ['process'], 'description': ['response to salt stress']}, {'category': ['process'], 'description': ['response to virus']}, {'category': ['process'], 'description': ['sequestering of triglyceride']}, {'category': ['process'], 'description': ['transformed cell apoptotic process']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}, {'id': ['BE0001087'], 'name': ['Lymphotoxin-alpha'], 'organism': ['Humans'], 'actions': [{'action': ['antibody']}], 'references': [{'articles': [{'article': [{'ref-id': ['A11581'], 'pubmed-id': ['11302411'], 'citation': ['Johnson CJ, Reilly KM, Murray KM: Etanercept in juvenile rheumatoid arthritis. Ann Pharmacother. 2001 Apr;35(4):464-71.']}, {'ref-id': ['A11583'], 'pubmed-id': ['15005015'], 'citation': ['Gudbrandsdottir S, Larsen R, Sorensen LK, Nielsen S, Hansen MB, Svenson M, Bendtzen K, Muller K: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2004 Jan-Feb;22(1):118-24.']}, {'ref-id': ['A11584'], 'pubmed-id': ['15033655'], 'citation': ['Buch MH, Conaghan PG, Quinn MA, Bingham SJ, Veale D, Emery P: True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis. 2004 Oct;63(10):1344-6. Epub 2004 Mar 19.']}]}], 'textbooks': [None], 'links': [{'link': [{'ref-id': ['L4237'], 'title': ['Enbrel (Etanercept) FDA Label'], 'url': ['https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf']}]}], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Lymphotoxin-alpha'], 'general-function': ['Receptor binding'], 'specific-function': ['Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.'], 'gene-name': ['LTA'], 'locus': ['6p21.3'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-34'], 'theoretical-pi': ['9.36'], 'molecular-weight': ['22296.57'], 'chromosome-location': ['6'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:6709']}, {'resource': ['GenAtlas'], 'identifier': ['LTA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X01393']}, {'resource': ['GenBank Protein Database'], 'identifier': ['34445']}, {'resource': ['UniProtKB'], 'identifier': ['P01374']}, {'resource': ['UniProt Accession'], 'identifier': ['TNFB_HUMAN']}]}], 'synonyms': [{'synonym': ['LT-alpha', 'TNF-beta', 'TNFB', 'TNFSF1', 'Tumor necrosis factor ligand superfamily member 1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010761|Lymphotoxin-alpha\nMTPPERLFLPRVCGTTLHLLLLGLLLVLLPGAQGLPGVGLTPSAAQTARQHPKMHLAHST\nLKPAAHLIGDPSKQNSLLWRANTDRAFLQDGFSLSNNSLLVPTSGIYFVYSQVVFSGKAY\nSPKATSSPLYLAHEVQLFSSQYPFHVPLLSSQKMVYPGLQEPWLHSMYHGAAFQLTQGDQ\nLSTHTDGIPHLVLSPSTVFFGAFAL'], 'gene-sequence': ['>lcl|BSEQ0010762|Lymphotoxin-alpha (LTA)\nATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTC\nCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTC\nACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACC\nCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGA\nGCAAACACGGACCGTGCCTTCCTCCAGGATGGTTTCTCCTTGAGCAACAATTCTCTCCTG\nGTCCCCACCAGTGGCATCTACTTCGTCTACTCCCAGGTGGTCTTCTCTGGGAAAGCCTAC\nTCTCCCAAGGCCACCTCCTCCCCACTCTACCTGGCCCATGAGGTCCAGCTCTTCTCCTCC\nCAGTACCCCTTCCATGTGCCTCTCCTCAGCTCCCAGAAGATGGTGTATCCAGGGCTGCAG\nGAACCCTGGCTGCACTCGATGTACCACGGGGCTGCGTTCCAGCTCACCCAGGGAGACCAG\nCTATCCACCCACACAGATGGCATCCCCCACCTAGTCCTCAGCCCTAGTACTGTCTTCTTT\nGGAGCCTTCGCTCTGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00229'], 'name': ['TNF']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['process'], 'description': ['apoptotic process']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['defense response to Gram-positive bacterium']}, {'category': ['process'], 'description': ['humoral immune response']}, {'category': ['process'], 'description': ['lymph node development']}, {'category': ['process'], 'description': ['negative regulation of fibroblast proliferation']}, {'category': ['process'], 'description': ['negative regulation of growth of symbiont in host']}, {'category': ['process'], 'description': ['positive regulation of apoptotic process']}, {'category': ['process'], 'description': ['positive regulation of chronic inflammatory response to antigenic stimulus']}, {'category': ['process'], 'description': ['positive regulation of glial cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of humoral immune response mediated by circulating immunoglobulin']}, {'category': ['process'], 'description': ['positive regulation of interferon-gamma production']}, {'category': ['process'], 'description': ['response to drug']}, {'category': ['process'], 'description': ['response to hypoxia']}, {'category': ['process'], 'description': ['response to lipopolysaccharide']}, {'category': ['process'], 'description': ['response to nutrient']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['tumor necrosis factor-mediated signaling pathway']}]}]}]}, {'id': ['BE0000710'], 'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['High affinity immunoglobulin gamma Fc receptor I'], 'general-function': ['Receptor signaling protein activity'], 'specific-function': ['High affinity receptor for the Fc region of immunoglobulins gamma. Functions in both innate and adaptive immune responses.'], 'gene-name': ['FCGR1A'], 'locus': ['1q21.2-q21.3'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['293-313'], 'signal-regions': ['1-15'], 'theoretical-pi': ['8.08'], 'molecular-weight': ['42631.525'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3613']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR1A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X14356']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31332']}, {'resource': ['UniProtKB'], 'identifier': ['P12314']}, {'resource': ['UniProt Accession'], 'identifier': ['FCGR1_HUMAN']}]}], 'synonyms': [{'synonym': ['Fc-gamma RI', 'Fc-gamma RIA', 'FCG1', 'FcgammaRIa', 'FCGR1', 'FcRI', 'IGFR1', 'IgG Fc receptor I']}], 'amino-acid-sequence': ['>lcl|BSEQ0001416|High affinity immunoglobulin gamma Fc receptor I\nMWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNG\nTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPL\nALRCHAWKDKLVYNVLYYRNGKAFKFFHWNSNLTILKTNISHNGTYHCSGMGKHRYTSAG\nISVTVKELFPAPVLNASVTSPLLEGNLVTLSCETKLLLQRPGLQLYFSFYMGSKTLRGRN\nTSSEYQILTARREDSGLYWCEAATEDGNVLKRSPELELQVLGLQLPTPVWFHVLFYLAVG\nIMFLVNTVLWVTIRKELKRKKKWDLEISLDSGHEKKVISSLQEDRHLEEELKCQEQKEEQ\nLQEGVHRKEPQGAT'], 'gene-sequence': ['>lcl|BSEQ0016183|High affinity immunoglobulin gamma Fc receptor I (FCGR1A)\nATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACA\nAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACC\nTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGC\nACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGT\nGGTGAATACAGGTGCCAGAGAGGTCTCTCAGGGCGAAGTGACCCCATACAGCTGGAAATC\nCACAGAGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCACGGAAGGAGAACCTCTG\nGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAAT\nGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATA\nAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACATCAGCAGGA\nATATCTGTCACTGTGAAAGAGCTATTTCCAGCTCCAGTGCTGAATGCATCTGTGACATCC\nCCACTCCTGGAGGGGAATCTGGTCACCCTGAGCTGTGAAACAAAGTTGCTCTTGCAGAGG\nCCTGGTTTGCAGCTTTACTTCTCCTTCTACATGGGCAGCAAGACCCTGCGAGGCAGGAAC\nACATCCTCTGAATACCAAATACTAACTGCTAGAAGAGAAGACTCTGGGTTATACTGGTGC\nGAGGCTGCCACAGAGGATGGAAATGTCCTTAAGCGCAGCCCTGAGTTGGAGCTTCAAGTG\nCTTGGCCTCCAGTTACCAACTCCTGTCTGGTTTCATGTCCTTTTCTATCTGGCAGTGGGA\nATAATGTTTTTAGTGAACACTGTTCTCTGGGTGACAATACGTAAAGAACTGAAAAGAAAG\nAAAAAGTGGGATTTAGAAATCTCTTTGGATTCTGGTCATGAGAAGAAGGTAATTTCCAGC\nCTTCAAGAAGACAGACATTTAGAAGAAGAGCTGAAATGTCAGGAACAAAAAGAAGAACAG\nCTGCAGGAAGGGGTGCACCGGAAGGAGCCCCAGGGGGCCACGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00047'], 'name': ['ig']}, {'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['clathrin-coated endocytic vesicle membrane']}, {'category': ['component'], 'description': ['early endosome membrane']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['receptor signaling protein activity']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent']}, {'category': ['process'], 'description': ['antigen processing and presentation of peptide antigen via MHC class I']}, {'category': ['process'], 'description': ['cytokine-mediated signaling pathway']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['interferon-gamma-mediated signaling pathway']}, {'category': ['process'], 'description': ['intracellular signal transduction']}, {'category': ['process'], 'description': ['phagocytosis, engulfment']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002098'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-a'], 'general-function': [None], 'specific-function': ['Binds to the Fc region of immunoglobulins gamma. Low affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens.'], 'gene-name': ['FCGR2A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-33'], 'theoretical-pi': ['6.78'], 'molecular-weight': ['35000.42'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3616']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M31932']}, {'resource': ['GenBank Protein Database'], 'identifier': ['182474']}, {'resource': ['UniProtKB'], 'identifier': ['P12318']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-a', 'Fc-gamma-RIIa', 'FCG2', 'FCGR2A1', 'FcRII-a', 'IGFR2', 'IgG Fc receptor II-a']}], 'amino-acid-sequence': ['>lcl|BSEQ0037156|Low affinity immunoglobulin gamma Fc region receptor II-a\nMTMETQMSQNVCPRNLWLLQPLTVLLLLASADSQAAAPPKAVLKLEPPWINVLQEDSVTL\nTCQGARSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSLSDPVHLTVL\nSEWLVLQTPHLEFQEGETIMLRCHSWKDKPLVKVTFFQNGKSQKFSHLDPTFSIPQANHS\nHSGDYHCTGNIGYTLFSSKPVTITVQVPSMGSSSPMGIIVAVVIATAVAAIVAAVVALIY\nCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQLEETNNDYETADGGYMTLNPRAPTDDD\nKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0019233|Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A)\nATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAA\nCCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAG\nGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTG\nACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAAT\nCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTCAAGGCCAACAACAATGACAGCGGG\nGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGCGACCCTGTGCATCTGACTGTGCTT\nTCCGAATGGCTGGTGCTCCAGACCCCTCACCTGGAGTTCCAGGAGGGAGAAACCATCATG\nCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTCAAGGTCACATTCTTCCAGAATGGA\nAAATCCCAGAAATTCTCCCATTTGGATCCCACCTTCTCCATCCCACAAGCAAACCACAGT\nCACAGTGGTGATTACCACTGCACAGGAAACATAGGCTACACGCTGTTCTCATCCAAGCCT\nGTGACCATCACTGTCCAAGTGCCCAGCATGGGCAGCTCTTCACCAATGGGGATCATTGTG\nGCTGTGGTCATTGCGACTGCTGTAGCAGCCATTGTTGCTGCTGTAGTGGCCTTGATCTAC\nTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTGAAGGCTGCCCAATTTGAG\nCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACTTGAAGAAACCAACAATGAC\nTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGGGCACCTACTGACGATGAT\nAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAACAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['innate immune response']}]}]}]}, {'id': ['BE0002099'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-b'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells. Binding to this receptor results in down-modulation of previous state of cell activation triggered via antigen receptors on B-cells (BCR), T-cells (TCR) or via another Fc receptor. Isoform IIB1 fails to mediate endocytosis or phagocytosis. Isoform IIB2 does not trigger phagocytosis.'], 'gene-name': ['FCGR2B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['218-240'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.12'], 'molecular-weight': ['34043.355'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3618']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['U87560']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4099445']}, {'resource': ['UniProtKB'], 'identifier': ['P31994']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-b', 'Fc-gamma-RIIb', 'FCG2', 'FcRII-b', 'IGFR2', 'IgG Fc receptor II-b']}], 'amino-acid-sequence': ['>lcl|BSEQ0004116|Low affinity immunoglobulin gamma Fc region receptor II-b\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISALPGYPECREMGETLPEKPANPTNPDEADKVGAENTITYSLLMHPDA\nLEEPDDQNRI'], 'gene-sequence': ['>lcl|BSEQ0019237|Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTG\nCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCC\nATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGGTTC\nAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTCAGC\nGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTGGAG\nTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTGGTC\nAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAACTTC\nTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATAGGC\nTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCACCG\nATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCTGTA\nGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATCCCACTAATCCTGATGAG\nGCTGACAAAGTTGGGGCTGAGAACACAATCACCTATTCACTTCTCATGCACCCGGATGCT\nCTGGAAGAGCCTGATGACCAGAACCGTATTTAG'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}, {'category': ['process'], 'description': ['signal transduction']}, {'category': ['process'], 'description': ['viral process']}]}]}]}, {'id': ['BE0002100'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13083'], 'pubmed-id': ['10800083'], 'citation': ['Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.']}, {'ref-id': ['A13087'], 'pubmed-id': ['7535196'], 'citation': ['Ranheim EA, Kipps TJ: Tumor necrosis factor-alpha facilitates induction of CD80 (B7-1) and CD54 on human B cells by activated T cells: complex regulation by IL-4, IL-10, and CD40L. Cell Immunol. 1995 Apr 1;161(2):226-35.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor II-c'], 'general-function': ['Transmembrane signaling receptor activity'], 'specific-function': ['Receptor for the Fc region of complexed immunoglobulins gamma. Low affinity receptor. Involved in a variety of effector and regulatory functions such as phagocytosis of immune complexes and modulation of antibody production by B-cells.'], 'gene-name': ['FCGR2C'], 'locus': ['1q23.3'], 'cellular-location': ['Cytoplasm'], 'transmembrane-regions': ['224-246'], 'signal-regions': ['1-42'], 'theoretical-pi': ['6.9'], 'molecular-weight': ['35577.96'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:15626']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR2C']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X17652']}, {'resource': ['GenBank Protein Database'], 'identifier': ['32074']}, {'resource': ['UniProtKB'], 'identifier': ['P31995']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG2C_HUMAN']}]}], 'synonyms': [{'synonym': ['CD32', 'CDw32', 'Fc-gamma RII-c', 'Fc-gamma-RIIc', 'FCG2', 'FcRII-c', 'IGFR2', 'IgG Fc receptor II-c']}], 'amino-acid-sequence': ['>lcl|BSEQ0004118|Low affinity immunoglobulin gamma Fc region receptor II-c\nMGILSFLPVLATESDWADCKSPQPWGHMLLWTAVLFLAPVAGTPAAPPKAVLKLEPQWIN\nVLQEDSVTLTCRGTHSPESDSIQWFHNGNLIPTHTQPSYRFKANNNDSGEYTCQTGQTSL\nSDPVHLTVLSEWLVLQTPHLEFQEGETIVLRCHSWKDKPLVKVTFFQNGKSKKFSRSDPN\nFSIPQANHSHSGDYHCTGNIGYTLYSSKPVTITVQAPSSSPMGIIVAVVTGIAVAAIVAA\nVVALIYCRKKRISANSTDPVKAAQFEPPGRQMIAIRKRQPEETNNDYETADGGYMTLNPR\nAPTDDDKNIYLTLPPNDHVNSNN'], 'gene-sequence': ['>lcl|BSEQ0011523|Low affinity immunoglobulin gamma Fc region receptor II-c (FCGR2C)\nATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAG\nTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTT\nGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAAC\nGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGAC\nTCCATTCCGTGGTTCCACAATGGGAATCTCATTCCCACCCACACGCAGCCCAGCTACAGG\nTTCAAGGCCAACAACAATGACAGCGGGGAGTACACGTGCCAGACTGGCCAGACCAGCCTC\nAGCGACCCTGTGCATCTGACTGTGCTTTCTGAGTGGCTGGTGCTCCAGACCCCTCACCTG\nGAGTTCCAGGAGGGAGAAACCATCGTGCTGAGGTGCCACAGCTGGAAGGACAAGCCTCTG\nGTCAAGGTCACATTCTTCCAGAATGGAAAATCCAAGAAATTTTCCCGTTCGGATCCCAAC\nTTCTCCATCCCACAAGCAAACCACAGTCACAGTGGTGATTACCACTGCACAGGAAACATA\nGGCTACACGCTGTACTCATCCAAGCCTGTGACCATCACTGTCCAAGCTCCCAGCTCTTCA\nCCGATGGGGATCATTGTGGCTGTGGTCACTGGGATTGCTGTAGCGGCCATTGTTGCTGCT\nGTAGTGGCCTTGATCTACTGCAGGAAAAAGCGGATTTCAGCCAATTCCACTGATCCTGTG\nAAGGCTGCCCAATTTGAGCCACCTGGACGTCAAATGATTGCCATCAGAAAGAGACAACCT\nGAAGAAACCAACAATGACTATGAAACAGCTGACGGCGGCTACATGACTCTGAACCCCAGG\nGCACCTACTGACGATGATAAAAACATCTACCTGACTCTTCCTCCCAACGACCATGTCAAC\nAGTAATAACTAA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['cytoplasm']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['transmembrane signaling receptor activity']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['signal transduction']}]}]}]}, {'id': ['BE0002097'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-A'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of IgG. Binds complexed or aggregated IgG and also monomeric IgG. Mediates antibody-dependent cellular cytotoxicity (ADCC) and other antibody-dependent responses, such as phagocytosis.'], 'gene-name': ['FCGR3A'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': ['209-229'], 'signal-regions': ['1-16'], 'theoretical-pi': ['8.21'], 'molecular-weight': ['29088.895'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3619']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3A']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X52645']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31324']}, {'resource': ['UniProtKB'], 'identifier': ['P08637']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3A_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16A', 'CD16a antigen', 'Fc-gamma RIII', 'Fc-gamma RIII-alpha', 'Fc-gamma RIIIa', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIa', 'IGFR3', 'IgG Fc receptor III-2']}], 'amino-acid-sequence': ['>lcl|BSEQ0004112|Low affinity immunoglobulin gamma Fc region receptor III-A\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYRVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVDDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKGRKYFHHNSDFYIPKATLKDSGSYFCRGLFGSKN\nVSSETVNITITQGLAVSTISSFFPPGYQVSFCLVMVLLFAVDTGLYFSVKTNIRSSTRDW\nKDHKFKWRKDPQDK'], 'gene-sequence': ['>lcl|BSEQ0011522|Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)\nATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCT\nTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTG\nCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCA\nAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACT\nCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAG\nAGCCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCGACGACAGT\nGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTGCAGCTAGAAGTC\nCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAGGAAGACCCTATT\nCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACATATTTACAGAAT\nGGCAAAGGCAGGAAGTATTTTCATCATAATTCTGACTTCTACATTCCAAAAGCCACACTC\nAAAGACAGCGGCTCCTACTTCTGCAGGGGGCTTTTTGGGAGTAAAAATGTGTCTTCAGAG\nACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCATCATTCTTTCCA\nCCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCAGTGGACACAGGA\nCTATATTTCTCTGTGAAGACAAACATTCGAAGCTCAACAAGAGACTGGAAGGACCATAAA\nTTTAAATGGAGAAAGGACCCTCAAGACAAATGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['external side of plasma membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['integral component of membrane']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['Fc-gamma receptor signaling pathway involved in phagocytosis']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['regulation of immune response']}]}]}]}, {'id': ['BE0000901'], 'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A13083'], 'pubmed-id': ['10800083'], 'citation': ['Hart SP, Ross JA, Ross K, Haslett C, Dransfield I: Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes. Cell Death Differ. 2000 May;7(5):493-503.']}, {'ref-id': ['A13084'], 'pubmed-id': ['17387033'], 'citation': ['Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F: Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine. 2007 May;74(3):249-53. Epub 2007 Mar 5.']}, {'ref-id': ['A13085'], 'pubmed-id': ['15457442'], 'citation': ['Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, Tiwari HK, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL Jr: The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004 Sep;50(9):2750-6.']}, {'ref-id': ['A13086'], 'pubmed-id': ['15526004'], 'citation': ['Hughes LB, Criswell LA, Beasley TM, Edberg JC, Kimberly RP, Moreland LW, Seldin MF, Bridges SL: Genetic risk factors for infection in patients with early rheumatoid arthritis. Genes Immun. 2004 Dec;5(8):641-7.']}, {'ref-id': ['A203909'], 'pubmed-id': ['19128982'], 'citation': ['Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, Louie JS, Kohno T: Differences in binding and effector functions between classes of TNF antagonists. Cytokine. 2009 Feb;45(2):124-31. doi: 10.1016/j.cyto.2008.11.008. Epub 2009 Jan 6.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Low affinity immunoglobulin gamma Fc region receptor III-B'], 'general-function': [None], 'specific-function': ['Receptor for the Fc region of immunoglobulins gamma. Low affinity receptor. Binds complexed or aggregated IgG and also monomeric IgG. Contrary to III-A, is not capable to mediate antibody-dependent cytotoxicity and phagocytosis. May serve as a trap for immune complexes in the peripheral circulation which does not activate neutrophils.'], 'gene-name': ['FCGR3B'], 'locus': ['1q23'], 'cellular-location': ['Cell membrane'], 'transmembrane-regions': [None], 'signal-regions': ['1-16'], 'theoretical-pi': ['6.71'], 'molecular-weight': ['26215.64'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3620']}, {'resource': ['GenAtlas'], 'identifier': ['FCGR3B']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X16863']}, {'resource': ['GenBank Protein Database'], 'identifier': ['31322']}, {'resource': ['UniProtKB'], 'identifier': ['O75015']}, {'resource': ['UniProt Accession'], 'identifier': ['FCG3B_HUMAN']}]}], 'synonyms': [{'synonym': ['CD16B', 'Fc-gamma RIII', 'Fc-gamma RIII-beta', 'Fc-gamma RIIIb', 'FCG3', 'FCGR3', 'FcR-10', 'FcRIII', 'FcRIIIb', 'IGFR3', 'IgG Fc receptor III-1']}], 'amino-acid-sequence': ['>lcl|BSEQ0010635|Low affinity immunoglobulin gamma Fc region receptor III-B\nMWQLLLPTALLLLVSAGMRTEDLPKAVVFLEPQWYSVLEKDSVTLKCQGAYSPEDNSTQW\nFHNESLISSQASSYFIDAATVNDSGEYRCQTNLSTLSDPVQLEVHIGWLLLQAPRWVFKE\nEDPIHLRCHSWKNTALHKVTYLQNGKDRKYFHHNSDFHIPKATLKDSGSYFCRGLVGSKN\nVSSETVNITITQGLAVSTISSFSPPGYQVSFCLVMVLLFAVDTGLYFSVKTNI'], 'gene-sequence': ['>lcl|BSEQ0010636|Low affinity immunoglobulin gamma Fc region receptor III-B (FCGR3B)\nATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACT\nGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAG\nGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGG\nTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACA\nGTCAACGACAGTGGAGAGTACAGGTGCCAGACAAACCTCTCCACCCTCAGTGACCCGGTG\nCAGCTAGAAGTCCATATCGGCTGGCTGTTGCTCCAGGCCCCTCGGTGGGTGTTCAAGGAG\nGAAGACCCTATTCACCTGAGGTGTCACAGCTGGAAGAACACTGCTCTGCATAAGGTCACA\nTATTTACAGAATGGCAAAGACAGGAAGTATTTTCATCATAATTCTGACTTCCACATTCCA\nAAAGCCACACTCAAAGATAGCGGCTCCTACTTCTGCAGGGGGCTTGTTGGGAGTAAAAAT\nGTGTCTTCAGAGACTGTGAACATCACCATCACTCAAGGTTTGGCAGTGTCAACCATCTCA\nTCATTCTCTCCACCTGGGTACCAAGTCTCTTTCTGCTTGGTGATGGTACTCCTTTTTGCA\nGTGGACACAGGACTATATTTCTCTGTGAAGACAAACATTTGA'], 'pfams': [{'pfam': [{'identifier': ['PF13895'], 'name': ['Ig_2']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['anchored component of membrane']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['mitophagy in response to mitochondrial depolarization']}, {'category': ['process'], 'description': ['positive regulation of defense response to virus by host']}, {'category': ['process'], 'description': ['xenophagy']}]}]}]}, {'id': ['BE0009995'], 'name': ['Complement component 1q (C1q)'], 'organism': ['Humans'], 'actions': [{'action': ['ligand']}], 'references': [{'articles': [{'article': [{'ref-id': ['A202010'], 'pubmed-id': ['27463856'], 'citation': ['Hofmann HP, Kronthaler U, Fritsch C, Grau R, Muller SO, Mayer R, Seidl A, Da Silva A: Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel((R))). Expert Opin Biol Ther. 2016 Oct;16(10):1185-95. doi: 10.1080/14712598.2016.1217329. Epub 2016 Aug 16.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['unknown'], 'polypeptide': [{'name': ['Complement C1q subcomponent subunit A'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QA'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-22'], 'theoretical-pi': ['9.45'], 'molecular-weight': ['26016.47'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1241']}, {'resource': ['GenAtlas'], 'identifier': ['C1QA']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF135157']}, {'resource': ['GenBank Protein Database'], 'identifier': ['4894854']}, {'resource': ['UniProtKB'], 'identifier': ['P02745']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QA_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit A precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016678|Complement C1q subcomponent subunit A\nMEGPRGWLVLCVLAISLASMVTEDLCRAPDGKKGEAGRPGRRGRPGLKGEQGEPGAPGIR\nTGIQGLKGDQGEPGPSGNPGKVGYPGPSGPLGARGIPGIKGTKGSPGNIKDQPRPAFSAI\nRRNPPMGGNVVIFDTVITNQEEPYQNHSGRFVCTVPGYYYFTFQVLSQWEICLSIVSSSR\nGQVRRSLGFCDTTNKGLFQVVSGGMVLQLQQGDQVWVEKDPKKGHIYQGSEADSVFSGFL\nIFPSA'], 'gene-sequence': ['>lcl|BSEQ0016679|Complement C1q subcomponent subunit A (C1QA)\nATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATG\nGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGC\nAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGG\nACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGC\nAAGGTGGGCTACCCAGGGCCCAGCGGCCCCCTCGGAGCCCGTGGCATCCCGGGAATTAAA\nGGCACCAAGGGCAGCCCAGGAAACATCAAGGACCAGCCGAGGCCAGCCTTCTCCGCCATT\nCGGCGGAACCCCCCAATGGGGGGCAACGTGGTCATCTTCGACACGGTCATCACCAACCAG\nGAAGAACCGTACCAGAACCACTCCGGCCGATTCGTCTGCACTGTACCCGGCTACTACTAC\nTTCACCTTCCAGGTGCTGTCCCAGTGGGAAATCTGCCTGTCCATCGTCTCCTCCTCAAGG\nGGCCAGGTCCGACGCTCCCTGGGCTTCTGTGACACCACCAACAAGGGGCTCTTCCAGGTG\nGTGTCAGGGGGCATGGTGCTTCAGCTGCAGCAGGGTGACCAGGTCTGGGTTGAAAAAGAC\nCCCAAAAAGGGTCACATTTACCAGGGCTCTGAGGCCGACAGCGTCTTCAGCGGCTTCCTC\nATCTTCCCATCTGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['cell-cell signaling']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}]}]}, {'name': ['Complement C1q subcomponent subunit B'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QB'], 'locus': ['1p36.12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-27'], 'theoretical-pi': ['8.87'], 'molecular-weight': ['26721.62'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1242']}, {'resource': ['GenAtlas'], 'identifier': ['C1QB']}, {'resource': ['GenBank Gene Database'], 'identifier': ['X03084']}, {'resource': ['GenBank Protein Database'], 'identifier': ['573114']}, {'resource': ['UniProtKB'], 'identifier': ['P02746']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QB_HUMAN']}]}], 'synonyms': [{'synonym': ['Complement C1q subcomponent subunit B precursor']}], 'amino-acid-sequence': ['>lcl|BSEQ0016676|Complement C1q subcomponent subunit B\nMMMKIPWGSIPVLMLLLLLGLIDISQAQLSCTGPPAIPGIPGIPGTPGPDGQPGTPGIKG\nEKGLPGLAGDHGEFGEKGDPGIPGNPGKVGPKGPMGPKGGPGAPGAPGPKGESGDYKATQ\nKIAFSATRTINVPLRRDQTIRFDHVITNMNNNYEPRSGKFTCKVPGLYYFTYHASSRGNL\nCVNLMRGRERAQKVVTFCDYAYNTFQVTTGGMVLKLEQGENVFLQATDKNSLLGMEGANS\nIFSGFLLFPDMEA'], 'gene-sequence': ['>lcl|BSEQ0016677|Complement C1q subcomponent subunit B (C1QB)\nATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGC\nCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATC\nCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGA\nGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCA\nGGGATTCCTGGGAATCCAGGAAAAGTCGGCCCCAAGGGCCCCATGGGCCCTAAAGGTGGC\nCCAGGGGCCCCTGGAGCCCCAGGCCCCAAAGGTGAATCGGGAGACTACAAGGCCACCCAG\nAAAATCGCCTTCTCTGCCACAAGAACCATCAACGTCCCCCTGCGCCGGGACCAGACCATC\nCGCTTCGACCACGTGATCACCAACATGAACAACAATTATGAGCCCCGCAGTGGCAAGTTC\nACCTGCAAGGTGCCCGGTCTCTACTACTTCACCTACCACGCCAGCTCTCGAGGGAACCTG\nTGCGTGAACCTCATGCGTGGCCGGGAGCGTGCACAGAAGGTGGTCACCTTCTGTGACTAT\nGCCTACAACACCTTCCAGGTCACCACCGGTGGCATGGTCCTCAAGCTGGAGCAGGGGGAG\nAACGTCTTCCTGCAGGCCACCGACAAGAACTCACTACTGGGCATGGAGGGTGCCAACAGC\nATCTTTTCCGGGTTCCTGCTCTTTCCAGATATGGAGGCCTGA'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['complement component C1 complex']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['inner ear development']}]}]}, {'name': ['Complement C1q subcomponent subunit C'], 'general-function': [None], 'specific-function': ['C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system. The collagen-like regions of C1q interact with the Ca(2+)-dependent C1r(2)C1s(2) proenzyme complex, and efficient activation of C1 takes place on interaction of the globular heads of C1q with the Fc regions of IgG or IgM antibody present in immune complexes.'], 'gene-name': ['C1QC'], 'locus': ['1p36.11'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-28'], 'theoretical-pi': ['8.58'], 'molecular-weight': ['25773.56'], 'chromosome-location': ['1'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:1245']}, {'resource': ['GenAtlas'], 'identifier': ['C1QC']}, {'resource': ['GenBank Gene Database'], 'identifier': ['AF087892']}, {'resource': ['GenBank Protein Database'], 'identifier': ['33150626']}, {'resource': ['UniProtKB'], 'identifier': ['P02747']}, {'resource': ['UniProt Accession'], 'identifier': ['C1QC_HUMAN']}]}], 'synonyms': [{'synonym': ['C1QG']}], 'amino-acid-sequence': ['>lcl|BSEQ0011520|Complement C1q subcomponent subunit C\nMDVGPSSLPHLGLKLLLLLLLLPLRGQANTGCYGIPGMPGLPGAPGKDGYDGLPGPKGEP\nGIPAIPGIRGPKGQKGEPGLPGHPGKNGPMGPPGMPGVPGPMGIPGEPGEEGRYKQKFQS\nVFTVTRQTHQPPAPNSLIRFNAVLTNPQGDYDTSTGKFTCKVPGLYYFVYHASHTANLCV\nLLYRSGVKVVTFCGHTSKTNQVNSGGVLLRLQVGEEVWLAVNDYYDMVGIQGSDSVFSGF\nLLFPD'], 'gene-sequence': ['>lcl|BSEQ0011521|Complement C1q subcomponent subunit C (C1QC)\nATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTG\nCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGC\nCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCA\nGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTA\nCCCGGCCATCCTGGGAAAAATGGCCCCATGGGACCCCCTGGGATGCCAGGGGTGCCCGGC\nCCCATGGGCATCCCTGGAGAGCCAGGTGAGGAGGGCAGATACAAGCAGAAATTCCAGTCA\nGTGTTCACGGTCACTCGGCAGACCCACCAGCCCCCTGCACCCAACAGCCTGATCAGATTC\nAACGCGGTCCTCACCAACCCGCAGGGAGATTATGACACGAGCACTGGCAAGTTCACCTGC\nAAAGTCCCCGGCCTCTACTACTTTGTCTACCACGCGTCGCATACAGCCAACCTGTGCGTG\nCTGCTGTACCGCAGCGGCGTCAAAGTGGTCACCTTCTGTGGCCACACGTCCAAAACCAAT\nCAGGTCAACTCGGGCGGTGTGCTGCTGAGGTTGCAGGTGGGCGAGGAGGTGTGGCTGGCT\nGTCAATGACTACTACGACATGGTGGGCATCCAGGGCTCTGACAGCGTCTTCTCCGGCTTC\nCTGCTCTTCCCCGACTAG'], 'pfams': [{'pfam': [{'identifier': ['PF01391'], 'name': ['Collagen']}, {'identifier': ['PF00386'], 'name': ['C1q']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['collagen trimer']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['process'], 'description': ['complement activation']}, {'category': ['process'], 'description': ['complement activation, classical pathway']}, {'category': ['process'], 'description': ['immune response']}, {'category': ['process'], 'description': ['innate immune response']}, {'category': ['process'], 'description': ['negative regulation of granulocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of macrophage differentiation']}]}]}]}]}]"
"['DB00006', 'BTD00076', 'EXPT03302', 'BIOD00076', 'DB02351']",['Bivalirudin'],small molecule,"['Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.']",['solid'],"['For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.']","['Inhibits the action of thrombin by binding both to its catalytic site and to its anion-binding exosite. Thrombin is a serine proteinase that plays a central role in the thrombotic process, acting to cleave fibrinogen into fibrin monomers and to activate Factor XIII to Factor XIIIa, allowing fibrin to develop a covalently cross-linked framework which stabilizes the thrombus; thrombin also activates Factors V and VIII, promoting further thrombin generation, and activates platelets, stimulating aggregation and granule release.']","[{'food-interaction': ['Avoid echinacea.', 'Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.']}]","[{'target': [{'id': ['BE0000048'], 'name': ['Prothrombin'], 'organism': ['Humans'], 'actions': [{'action': ['inhibitor']}], 'references': [{'articles': [{'article': [{'ref-id': ['A1733'], 'pubmed-id': ['11060732'], 'citation': ['Scatena R: Bivalirudin: a new generation antithrombotic drug. Expert Opin Investig Drugs. 2000 May;9(5):1119-27.']}, {'ref-id': ['A1736'], 'pubmed-id': ['11504570'], 'citation': ['Bates ER: Bivalirudin for percutaneous coronary intervention and in acute coronary syndromes. Curr Cardiol Rep. 2001 Sep;3(5):348-54.']}, {'ref-id': ['A1738'], 'pubmed-id': ['11833835'], 'citation': ['Gladwell TD: Bivalirudin: a direct thrombin inhibitor. Clin Ther. 2002 Jan;24(1):38-58.']}, {'ref-id': ['A1739'], 'pubmed-id': ['11923794'], 'citation': ['Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T: Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr;143(4):585-93.']}, {'ref-id': ['A1741'], 'pubmed-id': ['11929334'], 'citation': ['Carswell CI, Plosker GL: Bivalirudin: a review of its potential place in the management of acute coronary syndromes. Drugs. 2002;62(5):841-70.']}, {'ref-id': ['A9'], 'pubmed-id': ['11752352'], 'citation': ['Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.']}]}], 'textbooks': [None], 'links': [None], 'attachments': [None]}], 'known-action': ['yes'], 'polypeptide': [{'name': ['Prothrombin'], 'general-function': ['Thrombospondin receptor activity'], 'specific-function': ['Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing.'], 'gene-name': ['F2'], 'locus': ['11p11-q12'], 'cellular-location': ['Secreted'], 'transmembrane-regions': [None], 'signal-regions': ['1-24'], 'theoretical-pi': ['5.7'], 'molecular-weight': ['70036.295'], 'chromosome-location': ['11'], 'organism': ['Humans'], 'external-identifiers': [{'external-identifier': [{'resource': ['HUGO Gene Nomenclature Committee (HGNC)'], 'identifier': ['HGNC:3535']}, {'resource': ['GenAtlas'], 'identifier': ['F2']}, {'resource': ['GenBank Gene Database'], 'identifier': ['M17262']}, {'resource': ['GenBank Protein Database'], 'identifier': ['339641']}, {'resource': ['Guide to Pharmacology'], 'identifier': ['2362']}, {'resource': ['UniProtKB'], 'identifier': ['P00734']}, {'resource': ['UniProt Accession'], 'identifier': ['THRB_HUMAN']}]}], 'synonyms': [{'synonym': ['3.4.21.5', 'Coagulation factor II']}], 'amino-acid-sequence': ['>lcl|BSEQ0016004|Prothrombin\nMAHVRGLQLPGCLALAALCSLVHSQHVFLAPQQARSLLQRVRRANTFLEEVRKGNLEREC\nVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHV\nNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTTGPWCYTTDPTVRRQE\nCSIPVCGQDQVTVAMTPRSEGSSVNLSPPLEQCVPDRGQQYQGRLAVTTHGLPCLAWASA\nQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETG\nDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYI\nDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTEN\nDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHP\nVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDST\nRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKY\nGFYTHVFRLKKWIQKVIDQFGE'], 'gene-sequence': ['>lcl|BSEQ0016005|Prothrombin (F2)\nATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGC\nCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGG\nGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGC\nGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACG\nGATGTGTTCTGGGCCAAGTACACAGCTTGTGAGACAGCGAGGACGCCTCGAGATAAGCTT\nGCTGCATGTCTGGAAGGTAACTGTGCTGAGGGTCTGGGTACGAACTACCGAGGGCATGTG\nAACATCACCCGGTCAGGCATTGAGTGCCAGCTATGGAGGAGTCGCTACCCACATAAGCCT\nGAAATCAACTCCACTACCCATCCTGGGGCCGACCTACAGGAGAATTTCTGCCGCAACCCC\nGACAGCAGCACCACGGGACCCTGGTGCTACACTACAGACCCCACCGTGAGGAGGCAGGAA\nTGCAGCATCCCTGTCTGTGGCCAGGATCAAGTCACTGTAGCGATGACTCCACGCTCCGAA\nGGCTCCAGTGTGAATCTGTCACCTCCATTGGAGCAGTGTGTCCCTGATCGGGGGCAGCAG\nTACCAGGGGCGCCTGGCGGTGACCACACATGGGCTCCCCTGCCTGGCCTGGGCCAGCGCA\nCAGGCCAAGGCCCTGAGCAAGCACCAGGACTTCAACTCAGCTGTGCAGCTGGTGGAGAAC\nTTCTGCCGCAACCCAGACGGGGATGAGGAGGGCGTGTGGTGCTATGTGGCCGGGAAGCCT\nGGCGACTTTGGGTACTGCGACCTCAACTATTGTGAGGAGGCCGTGGAGGAGGAGACAGGA\nGATGGGCTGGATGAGGACTCAGACAGGGCCATCGAAGGGCGTACCGCCACCAGTGAGTAC\nCAGACTTTCTTCAATCCGAGGACCTTTGGCTCGGGAGAGGCAGACTGTGGGCTGCGACCT\nCTGTTCGAGAAGAAGTCGCTGGAGGACAAAACCGAAAGAGAGCTCCTGGAATCCTACATC\nGACGGGCGCATTGTGGAGGGCTCGGATGCAGAGATCGGCATGTCACCTTGGCAGGTGATG\nCTTTTCCGGAAGAGTCCCCAGGAGCTGCTGTGTGGGGCCAGCCTCATCAGTGACCGCTGG\nGTCCTCACCGCCGCCCACTGCCTCCTGTACCCGCCCTGGGACAAGAACTTCACCGAGAAT\nGACCTTCTGGTGCGCATTGGCAAGCACTCCCGCACCAGGTACGAGCGAAACATTGAAAAG\nATATCCATGTTGGAAAAGATCTACATCCACCCCAGGTACAACTGGCGGGAGAACCTGGAC\nCGGGACATTGCCCTGATGAAGCTGAAGAAGCCTGTTGCCTTCAGTGACTACATTCACCCT\nGTGTGTCTGCCCGACAGGGAGACGGCAGCCAGCTTGCTCCAGGCTGGATACAAGGGGCGG\nGTGACAGGCTGGGGCAACCTGAAGGAGACGTGGACAGCCAACGTTGGTAAGGGGCAGCCC\nAGTGTCCTGCAGGTGGTGAACCTGCCCATTGTGGAGCGGCCGGTCTGCAAGGACTCCACC\nCGGATCCGCATCACTGACAACATGTTCTGTGCTGGTTACAAGCCTGATGAAGGGAAACGA\nGGGGATGCCTGTGAAGGTGACAGTGGGGGACCCTTTGTCATGAAGAGCCCCTTTAACAAC\nCGCTGGTATCAAATGGGCATCGTCTCATGGGGTGAAGGCTGTGACCGGGATGGGAAATAT\nGGCTTCTACACACATGTGTTCCGCCTGAAGAAGTGGATACAGAAGGTCATTGATCAGTTT\nGGAGAGTAG'], 'pfams': [{'pfam': [{'identifier': ['PF00594'], 'name': ['Gla']}, {'identifier': ['PF00051'], 'name': ['Kringle']}, {'identifier': ['PF00089'], 'name': ['Trypsin']}, {'identifier': ['PF09396'], 'name': ['Thrombin_light']}]}], 'go-classifiers': [{'go-classifier': [{'category': ['component'], 'description': ['blood microparticle']}, {'category': ['component'], 'description': ['cytosol']}, {'category': ['component'], 'description': ['endoplasmic reticulum lumen']}, {'category': ['component'], 'description': ['extracellular exosome']}, {'category': ['component'], 'description': ['extracellular matrix']}, {'category': ['component'], 'description': ['extracellular region']}, {'category': ['component'], 'description': ['extracellular space']}, {'category': ['component'], 'description': ['Golgi lumen']}, {'category': ['component'], 'description': ['plasma membrane']}, {'category': ['function'], 'description': ['calcium ion binding']}, {'category': ['function'], 'description': ['growth factor activity']}, {'category': ['function'], 'description': ['receptor binding']}, {'category': ['function'], 'description': ['serine-type endopeptidase activity']}, {'category': ['function'], 'description': ['thrombospondin receptor activity']}, {'category': ['process'], 'description': ['acute-phase response']}, {'category': ['process'], 'description': ['blood coagulation']}, {'category': ['process'], 'description': ['blood coagulation, intrinsic pathway']}, {'category': ['process'], 'description': ['cell surface receptor signaling pathway']}, {'category': ['process'], 'description': ['cellular protein metabolic process']}, {'category': ['process'], 'description': ['cellular response to mechanical stimulus']}, {'category': ['process'], 'description': ['cytosolic calcium ion homeostasis']}, {'category': ['process'], 'description': ['fibrinolysis']}, {'category': ['process'], 'description': ['leukocyte migration']}, {'category': ['process'], 'description': ['multicellular organismal development']}, {'category': ['process'], 'description': ['negative regulation of astrocyte differentiation']}, {'category': ['process'], 'description': ['negative regulation of fibrinolysis']}, {'category': ['process'], 'description': ['negative regulation of platelet activation']}, {'category': ['process'], 'description': ['negative regulation of proteolysis']}, {'category': ['process'], 'description': ['peptidyl-glutamic acid carboxylation']}, {'category': ['process'], 'description': ['platelet activation']}, {'category': ['process'], 'description': ['positive regulation of blood coagulation']}, {'category': ['process'], 'description': ['positive regulation of cell growth']}, {'category': ['process'], 'description': ['positive regulation of cell proliferation']}, {'category': ['process'], 'description': ['positive regulation of collagen biosynthetic process']}, {'category': ['process'], 'description': ['positive regulation of phosphatidylinositol 3-kinase signaling']}, {'category': ['process'], 'description': ['positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway']}, {'category': ['process'], 'description': ['positive regulation of protein phosphorylation']}, {'category': ['process'], 'description': ['positive regulation of reactive oxygen species metabolic process']}, {'category': ['process'], 'description': ['positive regulation of release of sequestered calcium ion into cytosol']}, {'category': ['process'], 'description': ['post-translational protein modification']}, {'category': ['process'], 'description': ['proteolysis']}, {'category': ['process'], 'description': ['regulation of blood coagulation']}, {'category': ['process'], 'description': ['regulation of cell shape']}, {'category': ['process'], 'description': ['regulation of gene expression']}, {'category': ['process'], 'description': ['response to inactivity']}, {'category': ['process'], 'description': ['response to wounding']}]}]}]}]}]"
